S. 1954 · 119th Congress · Health

Biosimilar Red Tape Elimination Act

Reduces regulatory requirements for biosimilar drug approval. AI-read

Out of committee2.2k words Introduced Jun 4, 2025 · Latest action Jul 27, 2026

How far it has goneStage 3 of 6
  1. IntroducedJun 4, 2025 Done
  2. CommitteeReported Jul 27, 2026 Done
  3. Senate floorAwaiting vote Current stage
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products.

A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law. Further, the first biosimilar deemed interchangeable with a given reference product is awarded a period of marketing exclusivity.

The bill eliminates additional requirements for demonstrating interchangeability so that all licensed biosimilars are deemed interchangeable with their reference products. (Draft guidance released by the FDA in 2024 proposed to make some of these interchangeability requirements optional, including studies related to the safety of switching between use of the biosimilar and reference product. It has not been finalized.)

This change takes effect 60 days after the bill is enacted, and previously licensed biosimilars must be deemed interchangeable with their reference products on that date. However, the bill preserves the exclusivity period for first interchangeable biosimilars licensed before the bill’s enactment. For example, if a new biosimilar licensed after the bill takes effect relies on the same reference product as an existing biosimilar that is subject to an unexpired exclusivity period, the new biosimilar is not deemed interchangeable with the reference product until the exclusivity period has ended.

Congressional Research Service · summary of “Introduced in Senate” version · Jun 4, 2025

Who lobbies on it

15 organizations · 66 filings · Q2 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 6 of 6 quarters
    “S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red…”

    Q3 2026 filing · $26.6M lobbying spend in 2026 to date, all issues

  2. America's Health Insurance Plans Inc (ahip) 6 of 6 quarters
    “H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic…”

    Q3 2026 filing · $11.3M lobbying spend in 2026 to date, all issues

  3. Vizient Inc 5 of 6 quarters
    “Childrens Hospitals Graduate Medical Education (CHGME) program - Urged increased funding for CHGME to align the program levels with other federal physician training programs. Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological…”

    Q3 2026 filing · $940K lobbying spend in 2026 to date, all issues

12 more organizations, every filingPROUpgrade

Organizations that named S. 1954 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

5 actions · newest first
  1. Jul 27, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
  2. Jul 27, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
  3. Jun 17, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Jun 4, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Show all 5 actionsShow fewer
  1. Jun 4, 2025Introduced in Senate